Hypofractionated radiation therapy continues to expand across oncology, offering shorter treatment courses that maintain clinical effectiveness while improving convenience for patients. As departments advance toward hypofractionated and ultra hypofractionated schedules, clinicians are also rethinking the marking methods they use for daily alignment. InkRight® semi-permanent tattoos have emerged as an ideal match because they support accuracy and provide a better patient experience.
Unlike permanent tattoos, InkRight® Semi-Permanent Tattoos create a temporary mark that remains visible throughout a short-course of radiation therapy and then naturally fades. Since many hypofractionated plans last between five and twelve treatment days, InkRight offers exactly the durability clinicians need while avoiding long term cosmetic impact for patients.
Below is an overview of short-course treatments that align well with the wear time of InkRight®. These examples come directly from teams who shared the cases they treat most often.
Hypofractionated Treatment Types That Pair Well with InkRight
Prostate Cancer: Supported by National Guideline Consensus
Prostate cancer remains one of the highest volume disease sites in radiation therapy, and shorter treatment courses are well supported across major professional societies. The ASTRO Clinical Practice Guideline, the ACR Appropriateness Criteria, and the American Urological Association Guidelines all endorse hypofractionated radiation therapy as a safe and
effective option for localized prostate cancer when delivered under appropriate conditions.
These organizations collectively recognize moderate hypofractionation and stereotactic body radiation therapy as approachable options for many patients. Typical prostate hypofractionation schedules range from five fractions delivered over one to two weeks to moderately reduced schedules completed in three to four weeks.
These timelines fit naturally with the expected visibility of InkRight® semi-permanent tattoos, making them a logical marking method as more centers adopt guideline backed hypofractionated regimens.
Palliative and Symptom Management Treatments
Hypofractionated radiation is frequently used for symptom relief and pain management, especially in cases involving bone metastasis or palliative needs. These treatments often span one to five fractions or ten fractions completed in about twelve days, making InkRight an appropriate and patient friendly marking solution.
Benign and Non-Oncology Uses That Rely on Short-Course Care
Several non-oncology conditions treated with radiation therapy follow short-course schedules that pair well with InkRight. These include keloids, hypertrophic scars, osteoarthritis, Peyronie’s disease, and tendonitis. Most of these plans finish within one to two weeks, which aligns well with the visibility window of InkRight.
Why InkRight Is Well Suited for Hypofractionated Radiation Therapy
InkRight offers a temporary mark that lasts for the entire duration of a short-course radiation therapy plan and then naturally fades. This gives clinicians the reliable daily alignment they require without relying on permanent tattoos that remain long after treatment ends.
Patients also appreciate the non-invasive and temporary nature of InkRight. Many individuals prefer to avoid permanent tattoos tied to their cancer experience, and a semi-permanent option reduces anxiety while improving overall comfort. InkRight is also easy to apply and consistent across staff members, helping teams maintain a smooth workflow from simulation through treatment.
As hypofractionated and ultra hypofractionated radiation therapy continue to grow, InkRight® Semi-Permanent Tattoos offer a marking solution that supports clinical accuracy and patient comfort. They provide the visibility needed for daily setup while fading naturally after treatment, making them an ideal choice for many of today’s shorter radiation therapy schedules.
Contact your Radiation Therapy Account Manager at 1.800.233.5539 or info@beekley.com to learn more about InkRight or to request samples for a trial evaluation at your facility.
Megan Sargalski
Marketing Communications Specialist
